Cargando…
Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common cancer, and the third most common cause of cancer related death worldwide. The multi-kinase inhibitor Sorafenib represents the only systemic treatment option until today, and results from clinical trials with allosteric mTOR inhibitors were sob...
Autores principales: | Ewald, Florian, Nörz, Dominik, Grottke, Astrid, Bach, Johanna, Herzberger, Christiane, Hofmann, Bianca T., Nashan, Björn, Jücker, Manfred |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622849/ https://www.ncbi.nlm.nih.gov/pubmed/26535060 http://dx.doi.org/10.7150/jca.12452 |
Ejemplares similares
-
Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
por: Grabinski, Nicole, et al.
Publicado: (2012) -
Downregulation of AKT3 Increases Migration and Metastasis in Triple Negative Breast Cancer Cells by Upregulating S100A4
por: Grottke, Astrid, et al.
Publicado: (2016) -
Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
por: Woo, S-U, et al.
Publicado: (2017) -
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011) -
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
por: Li, Qingfang, et al.
Publicado: (2022)